{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:42:11Z","timestamp":1704714131083},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s13277-015-3832-1","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T00:10:21Z","timestamp":1438301421000},"page":"531-539","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Synergistic action of 5Z-7-oxozeaenol and bortezomib in inducing apoptosis of Burkitt lymphoma cell line Daudi"],"prefix":"10.1007","volume":"37","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haixia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayao","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongbin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,1]]},"reference":[{"key":"3832_CR1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","volume":"379","author":"EM Molyneux","year":"2012","unstructured":"Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. Lancet. 2012;379:1234\u201344.","journal-title":"Lancet"},{"key":"3832_CR2","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/sj.leu.2404753","volume":"21","author":"K Busch","year":"2007","unstructured":"Busch K, Keller T, Fuchs U, et al. Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t (8; 14) translocations in sporadic Burkitt-lymphoma. Leukemia. 2007;21:1739\u201351.","journal-title":"Leukemia"},{"key":"3832_CR3","doi-asserted-by":"crossref","first-page":"32338","DOI":"10.1074\/jbc.M004148200","volume":"275","author":"K Kanda","year":"2000","unstructured":"Kanda K, Hu H-M, Zhang L, Grandchamps J, Boxer LM. NF-\u03baB activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer. J Biol Chem. 2000;275:32338\u201346.","journal-title":"J Biol Chem"},{"issue":"7092","key":"3832_CR4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","volume":"441","author":"M Karin","year":"2006","unstructured":"Karin M. Nuclear factor-\u03baB in cancer development and progression. Nature. 2006;441(7092):431\u20136.","journal-title":"Nature"},{"key":"3832_CR5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539\u201345.","journal-title":"Lancet"},{"issue":"1","key":"3832_CR6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57\u201370.","journal-title":"Cell"},{"key":"3832_CR7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature02329","volume":"428","author":"I Garkavtsev","year":"2004","unstructured":"Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature. 2004;428:328\u201332.","journal-title":"Nature"},{"key":"3832_CR8","doi-asserted-by":"crossref","first-page":"10599","DOI":"10.1073\/pnas.92.23.10599","volume":"92","author":"I Alkalay","year":"1995","unstructured":"Alkalay I, Yaron A, Hatzubai A, Orian A, Ciechanover A, Ben-Neriah Y. Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci. 1995;92:10599\u2013603.","journal-title":"Proc Natl Acad Sci"},{"key":"3832_CR9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1126\/science.270.5244.2008","volume":"270","author":"K Yamaguchi","year":"1995","unstructured":"Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-\u03b2 signal transduction. Science. 1995;270:2008\u201311.","journal-title":"Science"},{"key":"3832_CR10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cdd.4401869","volume":"13","author":"Z Chen","year":"2006","unstructured":"Chen Z, Bhoj V, Seth R. Ubiquitin, TAK1 and IKK: is there a connection? Cell Death Differ. 2006;13:687\u201392.","journal-title":"Cell Death Differ"},{"key":"3832_CR11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden MS, Ghosh S. Shared principles in NF-\u03baB signaling. Cell. 2008;132:344\u201362.","journal-title":"Cell"},{"key":"3832_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1634\/theoncologist.11-1-51","volume":"11","author":"J San Miguel","year":"2006","unstructured":"San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006;11:51\u201361.","journal-title":"Oncologist"},{"key":"3832_CR13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.leu.2404278","volume":"20","author":"M Cavo","year":"2006","unstructured":"Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia. 2006;20:1341\u201352.","journal-title":"Leukemia"},{"key":"3832_CR14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"T-C Chou","year":"2006","unstructured":"Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621\u201381.","journal-title":"Pharmacol Rev"},{"key":"3832_CR15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2011-07-369397","volume":"120","author":"D Buglio","year":"2012","unstructured":"Buglio D, Palakurthi S, Byth K, et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood. 2012;120:347\u201355.","journal-title":"Blood"},{"key":"3832_CR16","first-page":"341","volume":"2008","author":"AS Perkins","year":"2008","unstructured":"Perkins AS, Friedberg JW. Burkitt lymphoma in adults. ASH Educ Program Book. 2008;2008:341\u20138.","journal-title":"ASH Educ Program Book"},{"key":"3832_CR17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/MOH.0b013e3281bccdee","volume":"14","author":"JT Yustein","year":"2007","unstructured":"Yustein JT, Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol. 2007;14:375\u201381.","journal-title":"Curr Opin Hematol"},{"key":"3832_CR18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1586\/14737140.6.3.373","volume":"6","author":"J Gerecitano","year":"2006","unstructured":"Gerecitano J, Straus DJ. Treatment of Burkitt lymphoma in adults. Expert Rev Anticancer Ther. 2006;6:373\u201381.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3832_CR19","first-page":"592","volume":"17","author":"X Yang","year":"2009","unstructured":"Yang X, Li X, Chen Y, et al. Apoptosis of Burkitt\u2019s lymphoma Raji cell line induced by bortezomib. Zhongguo shi yan xue ye xue za zhi\/Zhongguo bing li sheng li xue hui\u2009=\u2009J Exp Hematol\/Chinese Ass Pathophysiol. 2009;17:592\u20136.","journal-title":"Zhongguo shi yan xue ye xue za zhi\/Zhongguo bing li sheng li xue hui\u2009=\u2009J Exp Hematol\/Chinese Ass Pathophysiol"},{"key":"3832_CR20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1172\/JCI11991","volume":"107","author":"AS Baldwin","year":"2001","unstructured":"Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-\u03baB. J Clin Investig. 2001;107:241.","journal-title":"J Clin Investig"},{"key":"3832_CR21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1101\/gad.13.3.284","volume":"13","author":"E Spencer","year":"1999","unstructured":"Spencer E, Jiang J, Chen ZJ. Signal-induced ubiquitination of I\u03baB\u03b1 by the F-box protein Slimb\/\u03b2-TrCP. Genes Dev. 1999;13:284\u201394.","journal-title":"Genes Dev"},{"key":"3832_CR22","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/jnci\/djr243","volume":"103","author":"D Melisi","year":"2011","unstructured":"Melisi D, Xia Q, Paradiso G, et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst. 2011;103:1190\u2013204.","journal-title":"J Natl Cancer Inst"},{"key":"3832_CR23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2174\/156800911797264734","volume":"11","author":"S Martin","year":"2011","unstructured":"Martin S, Wu Z-H, Gehlhaus K, et al. RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Curr Cancer Drug Targets. 2011;11:976.","journal-title":"Curr Cancer Drug Targets"},{"key":"3832_CR24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cell.2011.12.033","volume":"148","author":"A Singh","year":"2012","unstructured":"Singh A, Sweeney MF, Yu M, et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012;148:639\u201350.","journal-title":"Cell"},{"key":"3832_CR25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/ni.2157","volume":"12","author":"N Ahmed","year":"2011","unstructured":"Ahmed N, Zeng M, Sinha I, et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol. 2011;12:1176\u201383.","journal-title":"Nat Immunol"},{"key":"3832_CR26","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s10495-013-0864-0","volume":"18","author":"Y Fan","year":"2013","unstructured":"Fan Y, Cheng J, Vasudevan SA, et al. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis. 2013;18:1224\u201334.","journal-title":"Apoptosis"},{"key":"3832_CR27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuro.2014.02.001","volume":"43","author":"A Ale","year":"2014","unstructured":"Ale A, Bruna J, Navarro X, Udina E. Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology. 2014;43:28\u201335.","journal-title":"Neurotoxicology"},{"key":"3832_CR28","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","volume":"112","author":"AA Argyriou","year":"2008","unstructured":"Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593\u20139.","journal-title":"Blood"},{"issue":"2","key":"3832_CR29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1586\/17474086.2014.899144","volume":"7","author":"S Grosicki","year":"2014","unstructured":"Grosicki S, Barchnicka A, Jurczyszyn A, Grosicka A. Bortezomib for the treatment of multiple myeloma. Expert Rev Hematol. 2014;7(2):173\u201385.","journal-title":"Expert Rev Hematol"},{"key":"3832_CR30","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","volume":"24","author":"PG Richardson","year":"2006","unstructured":"Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113\u201320.","journal-title":"J Clin Oncol"},{"key":"3832_CR31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32:634\u201340.","journal-title":"J Clin Oncol"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-015-3832-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3832-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-015-3832-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:29:29Z","timestamp":1559489369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-015-3832-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3832"],"URL":"https:\/\/doi.org\/10.1007\/s13277-015-3832-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,1]]}}}